Ars Pharmaceuticals Inc (SPRY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 297% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy
ARS Pharmaceuticals has experienced a >65% decline since my previous 'Hold' rating, reflecting significant commercialization challenges. SPRY's Q2/2026 report highlights the new CEO's plans to reinvigorate its FDA-approved no-needle epinephrine product, neffy. The company's high-risk profile remains evident, but the high-reward potential is now the more compelling of the two.
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
Ars Pharmaceuticals Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 400 | $5,800 | $2,052 | -$3,748 | -64.62% |
 Cyrus Pearo INVESTMENT MANAGEMENT ASSOCIATES Inc. /ADV | 359,074 | $4.01M | $1.84M | -$2.17M | -54.08% |
 Curtis Ellergodt Rothschild Investment LLC | 99 | $945.69 | $549.45 | -$396.24 | -41.9% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 92,875 | $1.26M | $552,606.25 | -$708,642.13 | -56.19% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 370 | $2,971.1 | $2,201.5 | -$769.6 | -25.9% |
Ars Pharmaceuticals Inc (SPRY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ars Pharmaceuticals Inc ever had a stock split?
Ars Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Donn Casale CEO | NASDAQ (NMS) Exchange | 82835W108 CUSIP |
| US Country | 195 Employees | - Last Dividend | - Last Split | 4 Dec 2020 IPO Date |
Overview
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. Established in 2015 and based in San Diego, California, the company is committed to improving the care and protection for patients experiencing life-threatening allergic reactions, also known as anaphylaxis. ARS Pharmaceuticals aims to serve a broad audience, including healthcare professionals, patients, and caregivers, by providing advanced, patient-friendly solutions for emergency situations.
Products and Services
neffy: The flagship product under development by ARS Pharmaceuticals, Inc. is neffy, a needle-free, intranasal epinephrine nasal spray designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Unlike traditional epinephrine auto-injectors, neffy offers a non-invasive, low-dose alternative that could transform the way severe allergic reactions are treated. The innovative nasal spray form aims to make administration less intimidating and more accessible in critical moments, thereby potentially increasing the likelihood of timely and effective treatment.
